US Liquid Biopsy Market Size, Trend and Growth Forecast

US Liquid Biopsy Market Introduction & Size Analysis:
The U.S. liquid biopsy market is projected to reach a value of US$10.5 billion by the end of 2031, rising from an anticipated US$4.1 billion in 2024, with a strong CAGR of 14.3% between 2024 and 2031.
Recent years have witnessed substantial growth in the U.S. liquid biopsy market sector, driven by technological advancements and an increase in the prevalence of cancer and chronic diseases. This surge has led to the growing adoption of liquid biopsies, which have gained significant attention and support in treatment planning due to their ability to provide accurate insights into a patient's cancer status.
Liquid biopsies are becoming increasingly vital in the United States due to their capacity to offer crucial information on the cancer's stage and spread, monitor treatment effectiveness, uncover the underlying causes of treatment resistance, and detect potential recurrences at an early stage.
Cancer remains the second leading cause of death in the U.S., with over 1.8 million new cases and more than 0.6 million cancer-related deaths annually. Early detection is essential to lowering treatment costs and improving survival rates.
There is a growing need for minimally invasive, early detection methods that can provide molecular diagnoses, enabling prompt patient stratification for the most appropriate treatment.